FI904975A0 - Tvaerbindade antikroppar och foerfaranden foer deras framstaellning. - Google Patents

Tvaerbindade antikroppar och foerfaranden foer deras framstaellning.

Info

Publication number
FI904975A0
FI904975A0 FI904975A FI904975A FI904975A0 FI 904975 A0 FI904975 A0 FI 904975A0 FI 904975 A FI904975 A FI 904975A FI 904975 A FI904975 A FI 904975A FI 904975 A0 FI904975 A0 FI 904975A0
Authority
FI
Finland
Prior art keywords
tvaerbindade
antikroppar
antibody
cross
tumour
Prior art date
Application number
FI904975A
Other languages
English (en)
Inventor
Stephen Keith Rhind
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1990/000214 external-priority patent/WO1990009196A1/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of FI904975A0 publication Critical patent/FI904975A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
FI904975A 1989-02-10 1990-10-09 Tvaerbindade antikroppar och foerfaranden foer deras framstaellning. FI904975A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898903022A GB8903022D0 (en) 1989-02-10 1989-02-10 Chemical compounds
PCT/GB1990/000214 WO1990009196A1 (en) 1989-02-10 1990-02-12 Cross-linked antibodies and processes for their preparation

Publications (1)

Publication Number Publication Date
FI904975A0 true FI904975A0 (fi) 1990-10-09

Family

ID=10651472

Family Applications (2)

Application Number Title Priority Date Filing Date
FI904975A FI904975A0 (fi) 1989-02-10 1990-10-09 Tvaerbindade antikroppar och foerfaranden foer deras framstaellning.
FI904974A FI904974A0 (fi) 1989-02-10 1990-10-09 Tvaerbundna antikroppar och processer foer deras framstaellning.

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI904974A FI904974A0 (fi) 1989-02-10 1990-10-09 Tvaerbundna antikroppar och processer foer deras framstaellning.

Country Status (16)

Country Link
EP (1) EP0384624B1 (fi)
JP (1) JP2975676B2 (fi)
KR (1) KR910700075A (fi)
AT (1) ATE123952T1 (fi)
AU (1) AU632536B2 (fi)
CA (1) CA2026312A1 (fi)
DE (1) DE69020182T2 (fi)
FI (2) FI904975A0 (fi)
GB (2) GB8903022D0 (fi)
HU (1) HUT56288A (fi)
IE (1) IE67320B1 (fi)
IL (1) IL93361A0 (fi)
NO (1) NO904367L (fi)
NZ (1) NZ232490A (fi)
WO (1) WO1990009195A1 (fi)
ZA (1) ZA90983B (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP2005181192A (ja) * 2003-12-22 2005-07-07 Tacmina Corp 残留塩素濃度測定方法
EP1750747A1 (en) 2004-05-07 2007-02-14 Astellas US LLC Soluble lfa-3 polypeptide for treating viral disorders
ES2358745T3 (es) 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
DE102005034950A1 (de) 2005-07-22 2007-02-01 Tesa Ag Abroller für die Herstellung eines Klebebandschlauchs
AU2007227218A1 (en) 2006-03-22 2007-09-27 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
GB2237020A (en) 1991-04-24
IE67320B1 (en) 1996-03-20
IE900494L (en) 1990-08-10
EP0384624A3 (en) 1990-11-14
HUT56288A (en) 1991-08-28
GB9021894D0 (en) 1990-11-28
KR910700075A (ko) 1991-03-13
EP0384624B1 (en) 1995-06-21
HU901641D0 (en) 1991-03-28
NO904367D0 (no) 1990-10-09
GB8903022D0 (en) 1989-03-30
ZA90983B (en) 1991-10-30
NZ232490A (en) 1992-09-25
JPH03504644A (ja) 1991-10-09
WO1990009195A1 (en) 1990-08-23
DE69020182T2 (de) 1995-11-30
JP2975676B2 (ja) 1999-11-10
ATE123952T1 (de) 1995-07-15
NO904367L (no) 1990-12-06
GB2237020B (en) 1993-04-14
AU5047590A (en) 1990-09-05
DE69020182D1 (de) 1995-07-27
FI904974A0 (fi) 1990-10-09
CA2026312A1 (en) 1990-08-11
EP0384624A2 (en) 1990-08-29
IL93361A0 (en) 1990-11-29
AU632536B2 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
GB8903021D0 (en) Chemical compounds
FI904975A0 (fi) Tvaerbindade antikroppar och foerfaranden foer deras framstaellning.
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
ATE162403T1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
GB9824632D0 (en) Biological compounds
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
DE69309472D1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE69232309T2 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
ATE255633T1 (de) Humane b-lymphoblastoiden zellinie welche anti- gangliosid-antikörper sekretiert
Rhind Crosslinked antibodies and processes for their preparation
IT1143135B (it) Agente per la diagnosi di tumori e procedimento per il suo trattamento
BR9815775A (pt) Anticorpos monoclonais anti-antìgeno carcinoembriÈnico (cea) humanizados de elevada afinidade
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: CELLTECH LIMITED